Thermo Fisher Scientific Inc. has expanded its European presence with a new ultra-cold facility designed to accelerate the development of advanced therapies. Situated in Bleiswijk, Netherlands, the current good manufacturing practice (cGMP) site offers comprehensive support for high-value therapies such as cell and gene therapies, biologics, antibodies, and vaccines.
The facility enhances the company’s contract manufacturing capabilities, providing bioservices and specialty logistics, including biorepository solutions and critical material storage. It is equipped to meet the clinical trial needs of both emerging biotech and established pharmaceutical companies, regardless of the trial’s scale or phase.
Molly Flick, vice president and general manager, bioservices & specialty logistics at Thermo Fisher Scientific, commented on the facility’s role in the industry: “The opening of this cutting-edge facility supporting the development of cell and gene therapies and other biologics… places us in an unmatched position to help our global clients develop innovative therapies.”
Located just 20 minutes from Rotterdam, the site offers a range of services from clinical and commercial packaging to end-to-end biorepository storage solutions. The 54,000 square feet facility includes ambient to cryogenic storage, cold chain packaging, labelling, distribution, and clinical QP release services, catering to the entire clinical supply chain.
